Previous 10 | Next 10 |
2024-02-15 12:18:48 ET Summary KalVista Pharmaceutical announces positive phase 3 data for its oral therapy, sebetralstat, for hereditary angioedema. Sebetralstat's rapid onset of symptom relief, oral administration, and favorable safety profile give it a competitive edge in the o...
2024-02-15 06:43:24 ET More on KalVista Pharmaceticals KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade) KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement Two biotech/pharma stocks to watch - ST...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii) pre-funded warrants to purchase 3,483,688 shares of common sto...
2024-02-14 16:29:45 ET KalVista Pharmaceuticals ( NASDAQ: KALV ) intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering. In additio...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) announced today that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering...
2024-02-14 14:31:52 ET Summary Sebetralstat has a compelling drug profile for the on-demand treatment of HAE attacks and could become the new standard of care in a billion-dollar market opportunity. KalVista is transitioning to a commercial company following positive Phase 3 data ...
2024-02-14 00:18:03 ET Read the full article on Seeking Alpha For further details see: Two Biotech/pharma stocks to watch - STTK, KALV
2024-02-13 08:18:56 ET DENVER, Colo., Feb. 13, 2024 ( www.247marketnews.com )- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) reported, this morning, positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat ...
2024-02-13 07:17:05 ET More on KalVista Pharmaceticals KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement Seeking Alpha’s Quant Rating on KalVista Pharmaceticals Historical earnings data for KalVista Pharmaceticals Financia...
– Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...